Leukemia - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
Preventing Respiratory Infections in Patients with CLL
(Posted: 10/21/2008) - This Featured Clinical Trial is a randomized, double-blind, placebo-controlled study to test the ability of CVT-E002 (COLD-fx) to reduce acute respiratory infections and the need for antibiotic treatment during the peak respiratory illness season (January through March) in people with chronic lymphocytic leukemia.
Inhibiting Tumor Angiogenesis in Children
(Posted: 01/22/2008) - In this trial, researchers are testing an angiogenesis inhibitor called cediranib in pediatric patients who have solid tumors (except brain tumors) or acute myeloid leukemia (AML), a type of blood cancer.
Targeted Therapy for Lymphoid Cancers
(Posted: 05/29/2007) - Patients with T-cell or B-cell lymphoid cancers that have recurred or progressed despite prior chemotherapy will receive the drug ABT-263 orally for up to a year in this phase I/II clinical trial.
Monoclonal Antibody Therapy for Treatment-Resistant Blood Cancers
(Posted: 03/29/2005, Updated: 05/16/2007) - This phase I dose-escalation study is investigating safety and tolerability of siplizumab, and will determine the maximum dose that can be given to patients with CD2-positive lymphoproliferative disease.
Comparing Treatments for Chronic Myelogenous Leukemia
(Posted: 02/13/2007) - In this trial, doctors will compare the effectiveness of imatinib (Gleevec) at the standard dose versus an increased dose and against a new drug called dasatinib (Sprycel) as initial therapy for chronic myelogenous leukemia.
(Posted: 10/21/2008) - This Featured Clinical Trial is a randomized, double-blind, placebo-controlled study to test the ability of CVT-E002 (COLD-fx) to reduce acute respiratory infections and the need for antibiotic treatment during the peak respiratory illness season (January through March) in people with chronic lymphocytic leukemia.
Inhibiting Tumor Angiogenesis in Children
(Posted: 01/22/2008) - In this trial, researchers are testing an angiogenesis inhibitor called cediranib in pediatric patients who have solid tumors (except brain tumors) or acute myeloid leukemia (AML), a type of blood cancer.
Targeted Therapy for Lymphoid Cancers
(Posted: 05/29/2007) - Patients with T-cell or B-cell lymphoid cancers that have recurred or progressed despite prior chemotherapy will receive the drug ABT-263 orally for up to a year in this phase I/II clinical trial.
Monoclonal Antibody Therapy for Treatment-Resistant Blood Cancers
(Posted: 03/29/2005, Updated: 05/16/2007) - This phase I dose-escalation study is investigating safety and tolerability of siplizumab, and will determine the maximum dose that can be given to patients with CD2-positive lymphoproliferative disease.
Comparing Treatments for Chronic Myelogenous Leukemia
(Posted: 02/13/2007) - In this trial, doctors will compare the effectiveness of imatinib (Gleevec) at the standard dose versus an increased dose and against a new drug called dasatinib (Sprycel) as initial therapy for chronic myelogenous leukemia.
